. Author manuscript; available in PMC: 2025 Feb 1.

Published in final edited form as: J Pediatr Gastroenterol Nutr. 2023 Dec 27;78(2):261–271. doi: 10.1002/jpn3.12074

Table 2.

Risk factors at enrollment for IFX discontinuation (n=219)

	Univariate		Multivariate
	HR(95%CI)	P value	HR(95%CI)	P value
Age	1.02(0.93-1.12)	0.63	1.00(0.89-1.11)	0.92
Female vs male	1.62(0.80-3.28)	0.18	1.71(0.78-3.76)	0.18
Body Mass Index	1.03(0.95-1.11)	0.49	1.04(0.95-1.14)	0.39
Combined immunotherapy
Never	1.00		1.00
Prior	0.64(0.25-1.62)	0.34	1.29(0.45-3.65)	0.63
Current	0.45(0.18-1.13)	0.09	1.25(0.41-3.78)	0.69
Detectable antibodies to Infliximab (ATI)^a	4.27(2.09-8.73)	<0.001	3.22(1.35-7.65)	0.008
Infliximab<5.0 μg/mL	3.18(1.56-6.49)	0.001	2.10(0.85-5.19)	0.11
CRP	1.31(1.05-1.63)	0.02	1.30(0.92-1.85)	0.14
Albumin	0.44(0.15-1.27)	0.13	1.29(034-4.99)	0.71
Type of IBD
Crohn's Disease	1.00		1.00
Ulcerative Colitis	2.96(1.41-6.20)	0.004	2.98(1.36-6.55)	0.007

Detectable Antibodies To Infliximab >3.1 U/mL